Sellas Life Sciences is trading 8% down at $9.76 today after disclosing it lost a binding arbitration case against 3D Medicines alongside its July 2026 earnings update.
- The company was ordered to pay damages and saw its claims dismissed in the 3D Medicines ruling, weighing on sentiment despite broader biotech sector strength.
- Sellas reported a robust cash position of $138.3 million, providing a projected financial runway through late 2028.